Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.37 |
| ▸ | CCR3 | P51677 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3153644 | 0.89 | MTNR1A (0.41) | SLC2A1KCNH2MTNR1AMTNR1BHTR2C | |
| SCHEMBL1267791 | 0.89 | SLC2A1 (0.40) | SLC2A1KCNH2MTNR1AMTNR1B | |
| SCHEMBL3541372 | 0.88 | KCNH2 (0.52) | SLC2A1KCNH2 | |
| SCHEMBL2937076 | 0.88 | KCNH2 (0.45) | SLC2A1KCNH2 | |
| SCHEMBL1082893 | 0.84 | KCNH2 (0.37) | SLC2A1KCNH2MTNR1AMTNR1BHTR2C | |
| SCHEMBL3155389 | 0.84 | MTNR1A (0.48) | SLC2A1KCNH2MTNR1AMTNR1BMCHR1 | |
| SCHEMBL3217443 | 0.82 | SLC2A1 (0.35) | SLC2A1KCNH2MTNR1AMTNR1BHTR2C | |
| SCHEMBL2821149 | 0.81 | SLC2A1 (0.44) | SLC2A1KCNH2MTNR1AMTNR1BMCHR1 | |
| SCHEMBL3753029 | 0.81 | SLC2A1 (0.33) | SLC2A1KCNH2MTNR1AMTNR1BHTR2C | |
| SCHEMBL3554235 | 0.80 | KCNH2 (0.45) | SLC2A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2276766-A1 | TRICYCLIC ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2011-01-26 | — | — | EP | disclosed |
| EP-2136807-B1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LTD (GB) | 2010-11-03 | — | — | EP | disclosed |
| EP-2176262-A1 | TRICYCLIC COMPOUNDS AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2010-04-21 | — | — | EP | disclosed |
| EP-1954697-B1 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-02-24 | — | — | EP | disclosed |
| EP-2136807-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | Glaxo Group Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| WO-2009128019-A1 | TRICYCLIC ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-22 | — | — | WO | disclosed |
| US-20080280892-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| WO-2008128962-A1 | TRICYCLIC COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008125594-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
| EP-1980251-A1 | Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis | GLAXO GROUP LIMITED (GB) | 2008-10-15 | — | — | EP | disclosed |
| US-20080221110-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
| EP-1954697-A2 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007081597-A2 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221110-A1 | Compounds | NRDC, NISCH, MRPL21 | SLC2A1 3396/4885KCNH2 3013/4885MTNR1A 3542/4885 |
| US-20080280892-A1 | Compounds | NRDC, NACA, NAA50 | SLC2A1 4172/4885KCNH2 3105/4885MTNR1A 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.